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Two randomised controlled trials reported earlier this year have demonstrated convincingly that bariatric surgery is effective in controlling hyperglycaemia in patients with type 2 diabetes. However, there is still a long way to go to determine if and how surgery should be used to treat diabetes. Mingrone et al.[@bib0005] randomised 60 patients to conventional medical treatment, gastric bypass or biliopancreatic diversion at the Day Hospital of Metabolic Diseases and Diabetology of the Catholic University in Rome. Schauer et al.[@bib0010] randomised 150 patients to optimal medical therapy, gastric bypass, or sleeve gastrectomy at the Cleveland Clinic, USA. Though they had slightly different end points, the results were dramatic in both. Schauer found that surgery caused a drop of glycated haemoglobin of up to 3% that was maintained at one year. In comparison, medical treatment was roughly half as effective, and this effect began to attenuate from 6 months despite the addition of more hypoglycaemic agents. Mingrone et al. defined diabetic remission at two years as a fasting plasma glucose of \<5.6 mmol/litre plus a glycated haemoglobin level of \<6.5% in the absence of pharmacological therapy. According to this definition, diabetic remission was induced in 75% of bypass patients and 95% of those undergoing biliopancreatic diversion, whilst remission occurred in no medical patients. Furthermore, both found that surgery was effective in inducing weight loss. Neither medical regimen induced significant weight loss whilst Schauer et al. found surgical patients lost one quarter of their weight, and Mingrone et al. found surgical patients lost one third. In fact, the great paradox of medical management of type 2 diabetes is that hypoglycaemic agents often led to weight gain.

The simultaneous publication of these trials has strengthened their impact. Alone, Mingrone\'s paper is limited because it uses conventional rather than optimal medical treatment. Conversely, Schauer\'s paper utilised intensive medical treatment in an experienced centre and, as such, may lack external validity. Together they demonstrate that surgery is more effective than medical regimens in controlling hyperglycaemia but more work is needed. Both were relative small, single centre studies. Neither study was powered to distinguish clinical outcomes -- surrogate endpoints, such as glycated haemoglobin levels and weight, were used. Later RCTs should quantify diabetic complications, morbidity, quality of life and cost in the short and long term. The launch of a national bariatric registry in the UK should help to address these questions.[@bib0015]

Ironically, although surgery may be an effective hypoglycaemic treatment, elucidating its mechanisms may yield novel pharmacological therapies that render surgery redundant. These mechanisms may include post-prandial incretin release.[@bib0020] However, the mechanisms are likely to be multifactorial, including mechanical effects and altered rates of absorption[@bib0020] -- which may in fact prove difficult to reproduce pharmacologically. Nevertheless, we understand that some surgeons feel that metabolic solutions in the near future make bariatric super-specialisation a risky career choice.
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